Evidence map›Paper›PMID 30733273›Full record

ArticleHaematologica2019

The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models.

Stuart W Hicks, Chiara Tarantelli, Alan Wilhem, Eugenio Gaudio, Min Li, Alberto J Arribas, Filippo Spriano, Roberta Bordone, Luciano Cascione, Katharine C Lai and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 43 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Advances in targeted therapy for malignant lymphoma.Signal transduction and targeted therapy · 2020
    Review
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 2 countries.

Stuart W HicksImmunoGen Inc., Waltham, MA, USA.
Chiara TarantelliUniversità della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland.
Alan WilhemImmunoGen Inc., Waltham, MA, USA.
Eugenio GaudioUniversità della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland.
Min LiImmunoGen Inc., Waltham, MA, USA.
Alberto J ArribasUniversità della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland.
Filippo SprianoUniversità della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland.
Roberta BordoneOncology Institute of Southern Switzerland, Bellinzona, Switzerland.
Luciano CascioneUniversità della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland.
Katharine C LaiImmunoGen Inc., Waltham, MA, USA.
Qifeng QiuImmunoGen Inc., Waltham, MA, USA.
Monica TaborelliCytogenetics Laboratory, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Davide RossiUniversità della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland.
Georg StussiOncology Institute of Southern Switzerland, Bellinzona, Switzerland.
Emanuele ZuccaOncology Institute of Southern Switzerland, Bellinzona, Switzerland.
Anastasios StathisOncology Institute of Southern Switzerland, Bellinzona, Switzerland.
Callum M SlossImmunoGen Inc., Waltham, MA, USA frbertoni@mac.com callum.sloss@immunogen.com.
Francesco BertoniUniversità della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland frbertoni@mac.com callum.sloss@immunogen.com.
ImmunoGen (United States) · USInstitute of Oncology Research · CHUniversità della Svizzera italiana · CHEnte Ospedaliero Cantonale · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody-drug conjugates (ADC) are a novel way to deliver potent cytotoxic compounds to cells expressing a specific antigen. Four ADC targeting CD19, including SAR3419 (coltuximab ravtansine), have entered clinical development. Here, we present huB4-DGN462, a novel ADC based on the SAR3419 anti-CD19 antibody linked

Indexed as

AnimalsAntibodies, Monoclonal, HumanizedAntigens, CD19Antineoplastic AgentsCell Line, TumorDisease Models, AnimalDose-Response Relationship, DrugFemaleHumansImmunoconjugatesLeukemiaLymphomaMaytansineMiceTreatment OutcomeXenograft Model Antitumor AssaysAntibodies, Monoclonal, HumanizedAntigens, CD19Antineoplastic Agentscoltuximab ravtansineImmunoconjugatesMaytansine

Identifiers

PMID30733273
PMCPMC6669148
OpenAlexW2912969574

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.